Table 1.
Patient characteristicsa
| Characteristics | Rheumatoid arthritis | Spondyloarthritides | ||
|---|---|---|---|---|
| Synovial fluid | Peripheral blood | Synovial fluid | Peripheral blood | |
| (n = 7) | (n = 14) | (n = 11) | (n = 30) | |
| Age, years | 34.8 ± 12.4 | 53.4 ± 14.5 | 32.4 ± 11.0 | 35.8 ± 13.2 |
| Disease duration, years | 4.4 ± 7.6 | 2.6 ± 8.2 | 6.6 ± 5.2 | 6.09 ± 5.91 |
| ESR, mm/hour | 59.3 ± 13.8 | 52.2 ± 26.0 | 36.8 ± 20.2 | 27.7 ± 21.5 |
| CRP, mg/mL | 6.1 ± 4.9 | 5.4 ± 1.6 | 3.6 ± 2.7 | 2.3 ± 3.2 |
| RF | 6/7+ | 12/14+ | 4/4- | 11/11- |
| Anti-CCP | 4/7+ | 8/14+ | 3/3- | 4/4- |
| HLA-B27 | Not done | Not done | 7/9+ | 21/26+ |
| DAS28 score | 5.6 ± 1.4 | 5.4 ± 1.8 | ||
| BASDAI score | 2.3 ± 2.1 | 3.9 ± 2.6 | ||
| DMARDs, n | All patients | 12 | 3 | None |
aESR = erythrocyte sedimentation rate; CRP = C-reactive protein; RF = rheumatoid factor; anti-CCP = anticyclic citrullinated peptide antibodies; HLA-B27 = human leucocyte antigen B27; DAS28 = disease activity score in 28 joints; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index (measured in AS patients only); DMARDs = disease-modifying antirheumatic drugs. Data are expressed as means ± standard deviations unless otherwise indicated.